Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Account Payables (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Change in Account Payables for 11 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 246.53% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 57.48% year-over-year, with the annual reading at $1.0 million for FY2025, 57.48% down from the prior year.
  • Change in Account Payables hit $2.9 million in Q4 2025 for Voyager Therapeutics, up from $312000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.0 million in Q1 2024 to a low of -$5.0 million in Q2 2024.
  • Historically, Change in Account Payables has averaged $218950.0 across 5 years, with a median of $215500.0 in 2022.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 6927.78% in 2022 and later tumbled 11427.78% in 2023.
  • Year by year, Change in Account Payables stood at -$18000.0 in 2021, then surged by 6927.78% to $1.2 million in 2022, then plummeted by 235.56% to -$1.7 million in 2023, then soared by 150.18% to $836000.0 in 2024, then surged by 246.53% to $2.9 million in 2025.
  • Business Quant data shows Change in Account Payables for VYGR at $2.9 million in Q4 2025, $312000.0 in Q3 2025, and -$830000.0 in Q2 2025.